Dr. Murphy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1520 San Pablo St
Suite 1000
Los Angeles, CA 90033Phone+1 323-442-5100
Education & Training
- Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 2005 - 2009
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2005
- Duke University School of MedicineClass of 2001
Certifications & Licensure
- CA State Medical License 2011 - 2027
- FL State Medical License 1983 - 2016
- NY State Medical License 2003 - 2016
- MA State Medical License 2006 - 2009
- PA State Medical License 1960 - 2001
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- 6 citationsDetection of HIV Virologic Failure and Switch to Second-Line Therapy: A Systematic Review and Meta-analysis of Data From Sub-Saharan Africa.Kerlly J Bernabé, Mark Siedner, Alexander C Tsai, Vincent C Marconi, Richard A Murphy
Open Forum Infectious Diseases. 2022-05-01 - 16 citationsIncreased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South AfricaHelen Bell Gorrod, Richard Court, Michael Schomaker, Gary Maartens, Richard A. Murphy
Journal of Acquired Immune Deficiency Syndromes. 2020-05-01 - 82 citationsAntimicrobial resistance in West Africa: a systematic review and meta-analysis.Kerlly J. Bernabé, Céline Langendorf, Nathan Ford, Jean-Baptiste Ronat, Richard A. Murphy
International Journal of Antimicrobial Agents. 2017-11-01
Press Mentions
- FDA Adviser Recommends Full Approval of Pfizer’s Covid Drug PaxlovidMarch 17th, 2023
- Advisors to the US Food and Drug Administration (FDA) Recommend Full Approval of Pfizer’s Covid Drug PaxlovidMarch 17th, 2023
- FDA Advisors Recommend Full Approval of Pfizer Covid Treatment Paxlovid for Adults 50 and over and Other High-Risk PeopleMarch 16th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: